[go: up one dir, main page]

PE20040581A1 - Inhibidores heterociclicos de cinasas - Google Patents

Inhibidores heterociclicos de cinasas

Info

Publication number
PE20040581A1
PE20040581A1 PE2003000622A PE2003000622A PE20040581A1 PE 20040581 A1 PE20040581 A1 PE 20040581A1 PE 2003000622 A PE2003000622 A PE 2003000622A PE 2003000622 A PE2003000622 A PE 2003000622A PE 20040581 A1 PE20040581 A1 PE 20040581A1
Authority
PE
Peru
Prior art keywords
kinase inhibitors
pyridin
methyl
compounds
heterocyclic kinase
Prior art date
Application number
PE2003000622A
Other languages
English (en)
Inventor
Rajeev S Bhide
John S Tokarski
Robert M Borzilleri
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20040581A1 publication Critical patent/PE20040581A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS FARMACEUTICOS DE FORMULA I DONDE A Y B SON CADA UNO ARILO, HETEROALRILO, HETEROCICLO, ENTRE OTROS; X E Y SON CADA UNO R1CR2, S, O, SO2, ENTRE OTROS; D ES S, O Y NR4; R1, R2 Y R4 SON CADA UNO H, ALQUILO, HETEROCICLO, ENTRE OTROS. SUS COMPUESTOS PREFERIDOS SON: 2,4-DIFLUORO-N-METIL-5-{[2-(PIRIDIN-2-ILAMINO)-TIAZOL-5-ILMETIL]-AMINO}-BENZAMIDA Y 4-FLUORO-N-METIL-3-{[2-(PIRIDIN-2-ILAMINO)-TIAZOL-5-ILMETIL]-AMINO}-BENZAMIDA; ENTRE OTROS. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE TIROSINA CINASA Y SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2003000622A 2002-06-20 2003-06-20 Inhibidores heterociclicos de cinasas PE20040581A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39081302P 2002-06-20 2002-06-20

Publications (1)

Publication Number Publication Date
PE20040581A1 true PE20040581A1 (es) 2004-09-08

Family

ID=30000629

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000622A PE20040581A1 (es) 2002-06-20 2003-06-20 Inhibidores heterociclicos de cinasas

Country Status (14)

Country Link
US (2) US7084160B2 (es)
EP (1) EP1513818B1 (es)
JP (1) JP4477492B2 (es)
AR (1) AR040272A1 (es)
AT (1) ATE455767T1 (es)
AU (1) AU2003251559A1 (es)
DE (1) DE60331061D1 (es)
ES (1) ES2337246T3 (es)
IS (1) IS7599A (es)
NO (1) NO330043B1 (es)
PE (1) PE20040581A1 (es)
PL (1) PL374272A1 (es)
TW (1) TW200401638A (es)
WO (1) WO2004001059A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
AU2003236557B2 (en) * 2002-06-27 2009-10-01 Verva Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
ATE450534T1 (de) * 2002-08-23 2009-12-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4823903B2 (ja) * 2003-07-11 2011-11-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンズイミダゾール誘導体
NZ546645A (en) 2003-10-23 2010-02-26 Ab Science 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7449167B2 (en) * 2004-07-08 2008-11-11 Air Products And Chemicals, Inc. Catalyst and process for improving the adiabatic steam-reforming of natural gas
CA2601706C (en) 2005-03-22 2016-09-20 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
EP2361624A1 (en) 2005-04-04 2011-08-31 AB Science Oxazole derivatives and their use as tyrosine kinase inhibitors
WO2006134989A1 (ja) * 2005-06-15 2006-12-21 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
US8337721B2 (en) 2005-12-02 2012-12-25 Vanderbilt University Broad-emission nanocrystals and methods of making and using same
JP5463036B2 (ja) 2005-12-21 2014-04-09 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬抗体組成物
WO2007071955A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Chemical compounds
ES2481413T3 (es) 2006-02-14 2014-07-30 The President And Fellows Of Harvard College Inhibidores de histona desacetilasa
CN101400362B (zh) 2006-02-14 2016-10-12 哈佛大学校长及研究员协会 双官能组蛋白去乙酰化酶抑制剂
CA2648216C (en) * 2006-04-13 2016-06-07 Michael Gutschow Tetrahalogenated compounds useful as inhibitors of angiogenesis
AU2007248656B2 (en) 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
CA2655997A1 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
JP5244118B2 (ja) 2006-11-10 2013-07-24 ブリストル−マイヤーズ スクイブ カンパニー 新規キナーゼ阻害剤
JP5286281B2 (ja) * 2007-01-05 2013-09-11 ブリストル−マイヤーズ スクイブ カンパニー アミノピラゾールキナーゼ阻害剤
WO2008084103A1 (en) * 2007-01-12 2008-07-17 Ab Science Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
BRPI0817527A2 (pt) 2007-10-01 2017-05-02 Isis Pharmaceuticals Inc modulação antissenso da expressão do receptor de fator de crescimento de fibroblasto humano 4
JP5535925B2 (ja) 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
WO2010011296A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2721156B1 (en) 2011-06-16 2016-12-21 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2016018795A1 (en) * 2014-07-28 2016-02-04 The General Hospital Corporation Histone deacetylase inhibitors
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017044858A2 (en) * 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
CN116751195B (zh) * 2023-06-21 2025-03-07 杭州科兴生物化工有限公司 联吡啶类化合物、其可药用的盐以及制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0841008A (ja) * 1994-07-29 1996-02-13 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP1087951B9 (en) * 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
WO2003091229A1 (en) 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
GEP20074148B (en) 2002-04-23 2007-07-10 Bristol Myers Squibb Co Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6951859B2 (en) 2002-08-02 2005-10-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
DE60331061D1 (de) 2010-03-11
AU2003251559A8 (en) 2004-01-06
US20060135576A1 (en) 2006-06-22
JP4477492B2 (ja) 2010-06-09
JP2005533808A (ja) 2005-11-10
ATE455767T1 (de) 2010-02-15
IS7599A (is) 2004-12-15
EP1513818B1 (en) 2010-01-20
ES2337246T3 (es) 2010-04-22
NO20045220L (no) 2005-01-19
TW200401638A (en) 2004-02-01
US7084160B2 (en) 2006-08-01
US7547711B2 (en) 2009-06-16
AR040272A1 (es) 2005-03-23
EP1513818A4 (en) 2006-10-04
WO2004001059A2 (en) 2003-12-31
PL374272A1 (en) 2005-10-03
EP1513818A2 (en) 2005-03-16
AU2003251559A1 (en) 2004-01-06
US20040077696A1 (en) 2004-04-22
WO2004001059A3 (en) 2004-03-04
NO330043B1 (no) 2011-02-07

Similar Documents

Publication Publication Date Title
PE20040581A1 (es) Inhibidores heterociclicos de cinasas
PE20040647A1 (es) Inhibidores de cinasas de tirosina
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
PE20090982A1 (es) Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
TR200000060T2 (tr) Bir N-fenil-2-pirimidinamin türevinin kristal modifikasyonu ve yapım işlemleri ve kullanımı.
DE60314639D1 (de) Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis
CY1111191T1 (el) Θεραπευτικος παραγοντας για την διαταραχη του κερατο-επιπεφυκοτα
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20040522A1 (es) Derivados de diarilurea dependientes de la cinasa de proteina
PE20120632A1 (es) Inhibidores de bace
ATE517874T1 (de) Pyrimidinone als modulatoren von caseinkinase ii (ck2)
TR200100917T2 (tr) Aril ve heteroaril sübstitüentli heteroksiklik üreler kullanılarak RAF kinazın inhibe edilmesi
ECSP045294A (es) Derivados de 2,4-diaminopirimidina
PE20020858A1 (es) Indanil aminas aciladas
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
AR017852A1 (es) COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER.
CY1108744T1 (el) 2-οξο-1,2,4,5-τετραϋδρo-1,3-βενζοδιαζεπιν-3-υλ-πιπεριδινες ως ανταγωνιστες της cgrp
PE20011259A1 (es) Derivado de piridina y pirimidina
ATE244235T1 (de) Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
PE20081059A1 (es) Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk)
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20050691A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa
PE20010491A1 (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
PE20040761A1 (es) Compuestos de pirrolotriazona
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa

Legal Events

Date Code Title Description
FC Refusal